menu
    • menu
    [{"orgOrder":0,"company":"Enyo Pharma","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"Vonafexor","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Enyo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Enyo Pharma \/ OrbiMed Advisors","highestDevelopmentStatusID":"8","companyTruncated":"Enyo Pharma \/ OrbiMed Advisors"},{"orgOrder":0,"company":"Enyo Pharma","sponsor":"Vesalius Biocapital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Series C Financing","leadProduct":"Vonafexor","moa":"FXR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Enyo Pharma","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Enyo Pharma \/ Vesalius Biocapital","highestDevelopmentStatusID":"8","companyTruncated":"Enyo Pharma \/ Vesalius Biocapital"}]

    Find Clinical Drug Pipeline Developments & Deals for F94108

    Menu

    F94108

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Enyo Pharma

                            France arrow
                            HPAPI Summit
                            Not Confirmed

                            Enyo Pharma

                            France arrow
                            HPAPI Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vonafexor

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Vesalius Biocapital

                            Deal Size : $36.8 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            ENYO Completes Series C to Advance Phase 2 Study in Alport Syndrome

                            Details : The proceeds will fund the ongoing ALPESTRIA-1 study evaluating EYP001 (vonafexor), a highly selective and oral FXR agonist, in patients with Alport syndrome.

                            Product Name : EYP001

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 12, 2025

                            Lead Product(s) : Vonafexor

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Vesalius Biocapital

                            Deal Size : $36.8 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Enyo Pharma

                            France arrow
                            HPAPI Summit
                            Not Confirmed

                            Enyo Pharma

                            France arrow
                            HPAPI Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vonafexor

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : OrbiMed Advisors

                            Deal Size : $42.5 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            ENYO Pharma Secures €39M in Series C and FDA Clearance for Vonafexor

                            Details : Financing will support the Phase 2 Alpestria-1 study and profiling of EYP001 (vonafexor), a selective NR1H4 agonist, in Autosomal Dominant Polycystic Kidney Disease (ADPKD).

                            Product Name : EYP001

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 01, 2024

                            Lead Product(s) : Vonafexor

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : OrbiMed Advisors

                            Deal Size : $42.5 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth